Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire (REACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03074435|
Recruitment Status : Unknown
Verified March 2017 by Cédric PENNETIER, Institut de Recherche pour le Developpement.
Recruitment status was: Enrolling by invitation
First Posted : March 8, 2017
Last Update Posted : March 10, 2017
|Condition or disease||Intervention/treatment||Phase|
|Malaria||Device: Insecticidal paint Device: Larvicide Biological: Ivermectin Behavioral: IEC||Phase 3|
Insecticidal paint comprised of two organophosphates (OPs) and an Insect Growth Regulator (IGR). This tool targets adult mosquitoes that are resistant pyrethroids to reduce vector density.
Larvicide is a new formulation of Bacillus thuringiensis israelensis that will be implemented in major permanent breeding sites with the objective to reduce vector density.
Ivermectin will be injected to domestic animals in addition to the national campaign implemented in the study area which treats the whole population. Ivermectin reduces the survival of mosquito that blood feed on treated humans and animals.
Information, Education and Communication strategy aims to increase the adherence of the population to control tools available. Strengthening the IEC aims to increase the good use of long lasting nets.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||18000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire: Research on Vector Control Strategies|
|Study Start Date :||April 2016|
|Estimated Primary Completion Date :||October 2017|
|Estimated Study Completion Date :||April 2019|
No Intervention: Control
Experimental: insecticidal paint
The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
Device: Insecticidal paint
Houses will be painted with insecticidal paint
Other Name: Inestfly 5A IGR
The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
Larval breeding sites will be treated with larvicide
This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
Doses of Ivermectin will be injected to peri-domestic animals
Experimental: Information, Education, Communication
After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
A reinforced information, education and communication strategy will be implemented.
- Malaria incidence [ Time Frame: continuous monitoring during 2 years ]Malaria cases reported in local health system
- Entomological Inoculation Rate [ Time Frame: Every 8 weeks during 2 years ]Number of infectious bites/personn
- Malaria prevalence [ Time Frame: Every 4 months during 2 years ]% of positive blood smears among the population between 6 months to 20 years
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03074435
|Principal Investigator:||Cédric Pennetier, PhD||Institut de Rehcerche pour le Développement|